Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study-Reference-Cited by-同舟云学术

Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

Published:2016-01-20 Issue:1 Volume:18 Page:
ISSN:1478-6362
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Park Won,Yoo Dae Hyun,Jaworski Janusz,Brzezicki Jan,Gnylorybov Andriy,Kadinov Vladimir,Sariego Irmgadt Goecke,Abud-Mendoza Carlos,Escalante William Jose Otero,Kang Seong Wook,Andersone Daina,Blanco Francisco,Hong Seung Suh,Lee Sun Hee,Braun Jürgen

Funder

CELLTRION Inc

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13075-016-0930-4

Reference32 articles.

1. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187–93.

2. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582–91.

3. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905–8.

4. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904.

5. Nast A, Mrowietz U, Kragballe K, de Jong EM, Puig L, Reich K, et al. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis—a multinational cross-sectional study. Arch Dermatol Res. 2013;305:899–907.

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting;Rheumatology and Therapy;2024-03-20

2. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System;RMD Open;2024-03

3. Explainable Artificial Intelligence (XAI): What we know and what is left to attain Trustworthy Artificial Intelligence;Information Fusion;2023-11

4. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis;Nature Reviews Rheumatology;2023-10-06

5. Korean treatment recommendations for patients with axial spondyloarthritis;The Korean Journal of Internal Medicine;2023-09-01